4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)

Lead compound THIO (ateganosine) is the only clinical-stage telomere-targeting anticancer agent throughout the field of cancer discovery Potential FDA filings in 2026 for accelerated approval from THIO-101 and early full approval from THIO-104 Full Shareholder Letter available in Investors section of MAIA's corporate website MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today published a 2025 Shareholder Letter by CEO Vlad Vitoc, M.D. detailing the Company's key milestones for 2025 including several clinical trials and regulatory pathways. "MAIA continues to bring innovation

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard cancer treatments and overcoming resistance MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the peer-reviewed scientific journal Naunyn-Schmiedeberg's Archives of Pharmacology. In a preclinical study, THIO and its new described dimer form were found to be potent inhibitors of Glutathione S-transferase Pi (GSTP1), a key enzyme implicated in cancer progression and chemoresis

Nonproprietary drug name approval marks essential step in FDA approval process MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the United States Adopted Names (USAN) Council has approved "ateganosine" as the nonproprietary (generic) name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment for advanced non-small cell lung cancer (NSCLC). The USAN Council is responsible for selecting standardized, informative and unique nonproprietary (generic) drug names. It is made up of experts from the America

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced plans to initiate a Phase 3 pivotal trial in 2025, named THIO-104, to evaluate the efficacy of THIO administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC) patients who are resistant to checkpoint inhibitors and chemotherapy. The multicenter, open-label, pivotal Phase 3 trial is designed to provide a direct comparison to chemotherapy in a 1:1 randomization of up to 300 patients. "THIO has consistently and substantially outperformed standard treatment options in our THIO-

Expansion study to enroll patients in the U.S. and select countries in Europe and Asia Multiple milestones attainable for 2025 MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer (NSCLC). Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. The THIO-101 s

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 952,300 shares of common stock at a purchase price of $1.50 per share, in a non-brokered private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $1.85 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,810,000 shares of common stock at a purchase price of $1.50 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $1.87 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to

Median overall survival (OS) from THIO treatment extends to 16.9 months Newest data strengthens regulatory strategy MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, sequenced with Regeneron's immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens. As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 1

CEO to detail THIO-101 expansion trial and upcoming trials in multiple indications MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chief Executive Officer Vlad Vitoc, M.D. will present at the Biotech Showcase™ 2025 investor conference taking place in San Francisco, California January 13-15, 2025. Dr. Vitoc will also host one-on-one meetings with investors throughout the 3-day event. The live event will be followed by a virtual 2-day event on January 21-22, 2025. At the conference, Dr. Vitoc will discuss MAIA's recent clinical developments and targeted value-dr

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire) Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hos

New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB). With over 20 years of academic and biopharmaceutical industry experience, Dr. Vezan is a highly regarded leader in drug development of novel therapeutic modalities, including cell and gene therapies, and played a pivotal role in the devel

DEFA14A - MAIA Biotechnology, Inc. (0001878313) (Filer)

DEF 14A - MAIA Biotechnology, Inc. (0001878313) (Filer)

8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

S-8 - MAIA Biotechnology, Inc. (0001878313) (Filer)

PRE 14A - MAIA Biotechnology, Inc. (0001878313) (Filer)

8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

424B5 - MAIA Biotechnology, Inc. (0001878313) (Filer)

8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

10-K - MAIA Biotechnology, Inc. (0001878313) (Filer)